Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of HSV-2 Therapeutic DNA Vaccines
NCT02030301Phase 2Completed
- Sponsor
- Vical Incorporated
- Start
- Dec 2013
- Primary completion
- Jun 2015
- Modality
- Viral Vector Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of VCL-HB01, VCL-HM01 in Genital Herpes Type 2 (HSV-2), sponsored by Vical Incorporated. Started Dec 2013; status: completed.
02
Drugs
VCL-HB01VCL-HM01
03
Conditions
Genital Herpes Type 2 (HSV-2)
Beyond the preview
Go deeper on NCT02030301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02030301.